Main navigation

• Home
• Our medicines
• Diseases and conditions
• Community support
• Help affording your medicines
• Research & development
• Healthcare professionals
• Careers
• About AstraZeneca US
  • Investors
  • Our company
  • AZ on the issues
  • Responsible business
  • Newsroom
    • Media resources
    • All news
    • Corporate news
    • Financial news
    • Product news
    • Research news
  • US web sites
  • Contact us

You are here

• Home
• About AstraZeneca US
• Newsroom

• Research news

The following shows headlines of all research-related news articles published within 12-months, starting from most recent.

• Pages
• 1
• 2
• Next

• • Nov 19, 2009
  • AstraZeneca submits US New Drug Application for ticagrelor (BRILINTA™), an investigational antiplatelet agent  
• • Nov 18, 2009
  • Results from two Phase II trials add to understanding of ticagrelor (BRILINTA™) and how it works in the body  
• • Nov 15, 2009
  • Ticagrelor (BRILINTA™) demonstrated greater efficacy over clopidogrel in the most urgent clinical setting: Patients with ST-Segment Elevation Myocardial Infarction and planned Percutaneous Coronary Intervention (PCI)  
• • Oct 28, 2009
  • Patients taking VIMOVO showed improved UGI tolerability assessments as compared to EC naproxen  
• • Oct 27, 2009
  • Phase 2 data from oral NKTR-118 presented at American College of Gastroenterology in San Diego  
• • Oct 19, 2009
  • Patients taking VIMOVO™ showed a decrease in incidence of NSAID-associated ulcers  
• • Sep 24, 2009
  • Ticagrelor reduced cardiovascular deaths and heart attacks in ACS patients undergoing heart procedures: New data from PLATO trial  
• • Aug 31, 2009
  • AstraZeneca announces FDA acceptance of New Drug Application for VIMOVO  
• • Aug 30, 2009
  • Phase III head to head trial showed ticagrelor reduced cardiovascular death and heart attacks over clopidogrel in acute coronary syndromes patients  
• • Aug 4, 2009
  • Project Zero Delay accelerates drug’s path to clinical trial  

• Pages
• 1
• 2
• Next

Page tools

• Print
• Bookmark this page
• Subscribe to RSS news feed